CLEOPATRA. Trastuzumab + docetaxel + placebo, n PHEREXA. Trastuzumab + capecitabine, n
|
|
- Preston Lawrence
- 5 years ago
- Views:
Transcription
1 Onkologikoa Foundation, San Sebastian, GEICAM, Spain; 2 Seoul National University, Seoul, Korea; 3 Hospital Clínic and Translational Genomics and Targeted Therapeutics in Solid Tumors IDIBAPS, Barcelona, GEICAM, Spain; 4 Memorial Sloan Kettering Cancer Center, New York, NY, USA; 5 Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA; 6 Roche Products Ltd., Welwyn Garden City, United Kingdom; 7 F. Hoffmann-La Roche Ltd., Basel, Switzerland; 8 Georgetown University Medical Center and Lombardi Comprehensive Cancer Center,, Washington, DC, USA. BC, breast cancer; EBC, early breast cancer; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; MBC, metastatic breast cancer;, category not collected in the respective study; PR, progesterone receptor; T-DM, trastuzumab emtansine. a versus no T-DM. CI, confidence interval; HR, hazard ratio; NR, not reached; OS, overall survival; T-DM, trastuzumab emtansine Received T-DM No T-DM Number at risk Month Received T-DM No T-DM OS, overall survival; T-DM, trastuzumab emtansine Received T-DM No T-DM Number at risk Month Received T-DM No T-DM OS, overall survival; T-DM, trastuzumab emtansine T-DM, trastuzumab emtansine. Additional Resources Efficacy of Trastuzumab Emtansine (T-DM) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Pertuzumab Ander Urruticoechea, Seock Ah Im, 2 Montserrat Munoz, 3 Jose Baselga, 4 Denise A Yardley, 5 Sarah Heeson, 6 Adam Knott, 6 Hannah Douthwaite, 6 Tanja Badovinac Crnjevic, 7 Sandra M Swain 8 23 Introduction T-DM is approved for the treatment of patients with human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer (MBC) previously treated with trastuzumab and a taxane based on the phase 3 EMILIA study Pertuzumab in combination with trastuzumab plus docetaxel is the first-line standard of care for HER2-positive MBC based on the CLEOPATRA study 2 The availability of data on the efficacy of T-DM in patients who were previously treated with pertuzumab is limited A retrospective, observational report of 78 patients in routine clinical practice showed a clinically-relevant benefit of T-DM in patients who previously received pertuzumab treatment. Physician-reported tumor response rate (non-recist) was 8%, and 3% of patients had a prolonged ( 6 months) duration of therapy. Furthermore, treatment outcomes were improved when T-DM was used as second-line or earlier treatment compared with use as later-than second-line treatment 3 To further evaluate the efficacy of T-DM in patients previously treated with pertuzumab, we conducted exploratory analyses using data obtained from patients who received T-DM at any time after pertuzumab in two phase 3 studies: CLEOPATRA and PHEREXA 2,4 6 CLEOPATRA examined first-line pertuzumab, trastuzumab, and docetaxel compared with trastuzumab plus docetaxel in patients with HER2-positive MBC 2,5,6 The addition of pertuzumab to trastuzumab + docetaxel led to a statistically significant improvement in median progression-free survival (PFS) by 6. months at the time of the primary analysis (median PFS of 2.4 months in the control arm versus 8.5 months in the pertuzumab arm; median follow-up 9.3 months for both arms) 2 In the final analysis of overall survival (OS), median OS was 56.5 months in the pertuzumab group and 4.8 months in the control group; thus, the addition of pertuzumab improved median OS by 5.7 months (median follow-up 49.5 months for the pertuzumab group and 5.6 months for the control group) 6 PHEREXA examined trastuzumab + capecitabine with or without pertuzumab for patients who progressed during/after line of trastuzumab-based therapy in the HER2-positive MBC setting 4 A 2-month increase in median PFS was observed with the pertuzumab-containing regimen, although these results were not statistically significant At the interim OS analysis, a numerical 8-month increase in median OS was observed with the pertuzumab regimen (median OS of 36. months) compared with the trastuzumab + capecitabine arm (median OS of 28. months), although confirmatory statistical testing was not performed due to the study statistical analysis plan Methods CLEOPATRA (NCT5679) and PHEREXA (NCT2642) are both phase 3, randomized, 2-arm trials evaluating pertuzumab-based regimens for the treatment of HER2-positive MBC CLEOPATRA study design: trastuzumab + docetaxel + pertuzumab versus trastuzumab + docetaxel + placebo in patients with no prior anti-her2 treatment or chemotherapy for MBC 2 PHEREXA study design: trastuzumab + capecitabine with or without pertuzumab in patients who progressed during/after previous trastuzumab treatment for MBC 4 The clinical databases for both CLEOPATRA and PHEREXA were queried for patients who, after experiencing disease progression, received T-DM treatment as a subsequent anti-cancer therapy versus patients who did not receive T-DM Patients with and without T-DM as subsequent anti-cancer therapy were identified from both the pertuzumab and control groups of each study Patients were allocated to the T-DM group if they had recorded trastuzumab emtansine as a subsequent anti-cancer therapy; otherwise, they were allocated to the no T-DM group Demographics and baseline characteristics were summarized for patients who received T-DM The exploratory analyses reported in this poster assessed OS, i.e., time from randomization to death at any point, in the T-DM and no T-DM groups For patients treated with pertuzumab, time from discontinuation of pertuzumab to initiation of T-DM and duration of T-DM treatment were also investigated Of note, case report forms did not collect the information that would be needed to evaluate overall response rate and PFS for T-DM as a subsequent anti-cancer therapy Results from these analyses are descriptive and no formal statistical comparisons have been made Limitations of analyses Collection of information on the use of subsequent anti-cancer therapies (including T-DM) was requested in both studies; however, this was not mandatory and, therefore, the information may not be complete Analyses of data are retrospective and based on limited information (n=75 patients reported receiving T-DM as subsequent therapy across both studies) Statistical analyses do not attempt to match patients with similar characteristics in the T-DM and no T-DM groups, which may lead to potential bias in the patient/disease characteristics between groups Patients who died during randomized therapy or who otherwise had not received subsequent therapy at the time of the analysis cutoff have been included in the no TDM group Results Patients Of 48 patients who received trastuzumab + docetaxel + pertuzumab in CLEOPATRA and 228 patients who received trastuzumab + capecitabine + pertuzumab in PHEREXA, 32 and 43 patients, respectively, received subsequent treatment with T-DM Demographics and baseline characteristics of patients with subsequent T-DM treatment are summarized in Table Table. Demographic and baseline characteristics of patients treated with T-DM as a subsequent anti-cancer therapy from CLEOPATRA and PHEREXA CLEOPATRA PHEREXA Trastuzumab + Trastuzumab + Trastuzumab + docetaxel + docetaxel + Trastuzumab + capecitabine + placebo pertuzumab capecitabine pertuzumab n (%) (n=34) (n=32) (n=39) (n=43) Prior treatment status EBC 9 (55.9) 4 (43.8) 4 (.3) 4 (9.3) De novo BC 5 (44.) 8 (56.3) MBC 8 (46.2) 2 (46.5) EBC and MBC 7 (43.6) 9 (44.2) Disease type at screening Visceral disease 3 (88.2) 24 (75.) 23 (59.) 23 (53.5) Non-visceral disease 4(.8) 8 (25.) 6 (4.) 2 (46.5) ER/PR Status Positive 4 (4.2) 5 (46.9) 23 (59.) 23 (53.5) Negative 9 (55.9) 7 (53.) 4 (35.9) 9 (44.2) Unknown (2.9) 2 (5.) (2.3) No. of prior HER2 therapies before study randomization 24 (7.6) 28 (87.5) (29.4) 4 (2.5) 39 () 43 () Efficacy There was a numerical difference in median OS between those who received T-DM as a subsequent therapy and those who did not receive T-DM (Table 2, Figures and 2) In the trastuzumab + docetaxel + pertuzumab arm of CLEOPATRA, median OS was not reached for patients who received T-DM and 6.4 months for patients who did not receive T-DM In the trastuzumab + capecitabine + pertuzumab arm of PHEREXA, median OS was 38.3 months for patients who received T-DM and 32.8 months for patients who did not receive T-DM The median time from discontinuation of pertuzumab to initiation of T-DM in CLEOPATRA and PHEREXA was 3.5 months and.6 months, respectively (Table 3) The median duration of T-DM treatment was 7. months and 4.2 months in CLEOPATRA and PHEREXA, respectively (Table 3) Table 2. Overall survival by receipt of T-DM as a subsequent anti-cancer therapy No T-DM T-DM CLEOPATRA Trastuzumab + docetaxel + placebo, n (54.7) 2 (58.8) 39.6 (35 47) 46.2 (34 57).93 (.58.49) Trastuzumab + docetaxel + pertuzumab, n (42.) (34.4) 6.4 (49 NR) NR (49 NR).62 (.33.4) PHEREXA Trastuzumab + capecitabine, n (54.7) 6 (4.) 23.7 (2 29) 4. (3 57).45 (.26.8) Trastuzumab + capecitabine + pertuzumab, n (44.3) 6 (37.2) 32.8 (28 39) 38.3 (34 NR).53 (.3.94) Figure. Kaplan Meier curve of OS (in months) for patients in CLEOPATRA who received pertuzumab and subsequently received T-DM versus those who did not Proportion surviving Figure 2. Kaplan Meier curve of OS (in months) for patients in PHEREXA who received pertuzumab and subsequently received T-DM versus those who did not Proportion surviving Table 3. Duration of T-DM and time between stopping pertuzumab treatment to start of treatment with T-DM Trastuzumab + docetaxel + Trastuzumab + capecitabine + pertuzumab (CLEOPATRA) pertuzumab (PHEREXA) Median months (range) n=32 n=43 Duration of T-DM 7. ( 44) 4.2 ( 22) Time from discontinuation of study drug to start of T-DM 3.5 ( 47).2 ( 28) Time from randomization to start of T-DM 27 (6 59) 2. (8 52) Discussion and Conclusions These exploratory, retrospective analyses of data from CLEOPATRA and PHEREXA suggest that patients who received T-DM as a subsequent therapy following disease progression on pertuzumab + trastuzumab had numerically longer OS than those who did not receive T-DM as a subsequent therapy In CLEOPATRA, patients had a median treatment duration of T-DM of 7. months; whereas, in PHEREXA median treatment duration was 4.2 months This finding may be due to differences in the lines of therapy in which T-DM was received within these trials, as the studies had different designs: the majority of patients receiving T-DM after discontinuation from the CLEOPATRA study were likely treated in the second- or third-line setting, whereas, for PHEREXA, patients were likely treated with T-DM in a later setting Interpretation of results should be made with caution As noted earlier, there are multiple limitations associated with the present analysis Differences between the CLEOPATRA and PHEREXA studies may impact the data presented herein, including differences in study design and patient population, timing, and location, as well as the availability/approval statuses of the various treatments studied The duration of T-DM therapy in patients previously treated with pertuzumab appeared to be longer when T-DM was given earlier in comparison with use in later lines. These results are consistent with prior studies conducted in the respective second- and third-line settings,6 and provide further support for early use of T-DM in the therapeutic sequence for patients with HER2-positive MBC References. Verma S, et al. N Engl J Med. 22;367: Swain SM, et al; CLEOPATRA Study Group. Lancet Oncol. 2. Baselga J, et al; CLEOPATRA Study Group. N Engl J Med. 23;4: ;366: Swain SM, et al; CLEOPATRA Study Group. N Engl J Med. 3. Dzimitrowicz H, et al. J Clin Oncol. 26 Jun 3 [Epub ahead 25;372: of print]. 7. Krop IE, et al. Lancet Oncol. 24; 5: Urruticoechea A, et al. J Clin Oncol. 27 Apr 24 [Epub ahead of print]. Acknowledgments Funding for the CLEOPATRA and PHEREXA studies is provided by Genentech, Inc./F. Hoffmann-La Roche Ltd. Third-party writing assistance was provided by Meredith Kalish, MD, of CodonMedical, an Ashfield Company, part of the UDG Healthcare plc, and funded by F. Hoffman-La Roche Ltd. Please contact Ander Urruticoechea (anderu@onkologikoa.org) with questions and comments. Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from ASCO and the author of this poster. ES/KAD/77/34 American Society of Clinical Oncology Annual Meeting; June 2 6, 27; Chicago, IL. MetaPHER: A phase IIIb multicenter, open-label, single-arm safety study of subcutaneous trastuzumab, in combination with pertuzumab and docetaxel in patients with HER2-positive advanced breast cancer. Sant Antonio Breast Cancer Symposium 26 poster OT3--3. BACKGROUND: In patients (pts) with HER2-positive metastatic breast cancer (BC), the phase III CLEOPATRA study (NCT5679) demonstrated significant improvement in progression-free (PFS) and overall survival (OS) from firstline treatment with intravenous (IV) pertuzumab (PERJETA [P IV]) plus trastuzumab (Herceptin [H IV]) plus docetaxel (D IV). HannaH (NCT953), a phase III trial in pts with HER2-positive early BC demonstrated that fixed-dose trastuzumab subcutaneous (Herceptin [H SC]) is non-inferior to weight-based H IV infusion in the co-primary endpoints of serum trough concentration and pathologic complete response, which was supported by the long-term efficacy endpoints of event-free survival (EFS) and OS. The safety profile of H SC was consistent with the known safety profile of H IV. H SC is comprised of 6 mg trastuzumab and recombinant human hyaluronidase (rhuph2) as an excipient, allowing a significantly reduced administration time compared with H IV (5 mins versus 3 9 mins, respectively). The MetaPHER study is designed to investigate the safety and efficacy of H SC in combination with P IV and D IV in pts with HER2-positive advanced BC. TRIAL DESIGN: MetaPHER is a phase IIIb multicenter, open-label, single-arm study, with eligible pts receiving H SC 6 mg/5 ml q3w, P IV (84 mg loading dose, then 42 mg at each subsequent cycle q3w), and D IV (at least 6 cycles at 75 mg/m² q3w with possible escalation to mg/m² q3w; after Cycle 6, continuation of docetaxel is at the investigator s discretion). Study treatment is administered until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined study end, whichever occurs first. Pts will receive post-treatment follow-up for safety and survival. ELIGIBILITY: Women aged 8 years with metastatic or locally recurrent HER2- positive BC, ECOG performance status or, and a left ventricular ejection fraction 5% are eligible. Exclusion criteria include disease-free interval of <6 months from completion of adjuvant or neoadjuvant non-hormonal treatment to disease recurrence; previous systemic nonhormonal therapy for metastatic or locally recurrent BC; history of persistent grade 2 hematological toxicity; current grade 3 peripheral neuropathy; or clinically significant cardiovascular disease. AIMS: The primary objective is to evaluate the safety and tolerability of H SC in combination with P IV and D IV in pts with HER2-positive advanced BC. Secondary endpoints include PFS, OS, objective response rate and incidence of anti-trastuzumab and anti-rhuph2 antibody formation. STATISTICAL METHODS: Safety and efficacy results will be summarized descriptively to include all enrolled pts who received at least one dose of any study drug; the study is not designed for formal hypothesis testing. A sample size of 4 pts provides reasonable precision for the estimation of grade 3 AEs and cardiac AEs.
2 2. Loi S, Giobbe-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, Andre F. International Breast Cancer Study Group and Breast International Group. Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PACEA (IBCSG 45-3/BIG 4-3/KEYNOTE-4) study. DOI:.58/ SABCS7-GS2-6. BACKGROUND: Preclinical and clinical data suggest that HER2-positive (HER2+) breast cancer (BC) will be amendable to immunotherapeutic approaches. We evaluated pembrolizumab with trastuzumab in patients (pts) with trastuzumab-resistant HER2+, PD-L positive (PD-Lpos), unresectable loco-regional or metastatic BC and a parallel cohort of pts with HER2+, PD-L negative (PD-Lneg) BC during the phase II study. METHODS: Pts with advanced BC and progression on prior trastuzumab-based therapies, ECOG, and a metastatic tumor biopsy in the last year were eligible. HER2 positivity and quantity of tumorinfiltrating lymphocytes (TILs) on H&E slide were centrally evaluated. PD-L score was assessed by Merck central lab. Tumor imaging was performed at weeks 2, 8, 24 and every 2 weeks, thereafter. Primary endpoints were safety of the combination (phase Ib) and objective response rate (ORR) per RECIST. (phase II). Secondary endpoints were PFS, duration of response, and OS. Phase Ib was a 3+3 dose-escalation of 2 pembrolizumab doses (2 mg/kg, mg/kg) Q3W. In phase II, pts received pembrolizumab 2 mg Q3W for 24 months or until disease progression. Clinically stable pts with progression were allowed to continue pembrolizumab until confirmation on subsequent assessment. Pts with isolated CNS progression were also allowed to continue pembrolizumab after local treatment. Planned total enrollment was 6 pts. For the phase II PD- Lpos cohort, a Simon two-stage design (N = 4; proceed if 2/7 respond) was used which had 85% power to compare ORR of 7% vs. 22% (-sided α =.5). For the PD- Lneg cohort, a single-stage design with 5 pts had >95% power to compare ORR of % vs. 2% (-sided α =.4). Clinicaltrials.gov: NCT RESULTS: 6 pts enrolled in phase Ib between April and July 25; no DLTs were observed. The PD-Lpos cohort enrolled 4 pts between August 25 and September 26. The PD-Lneg cohort enrolled May 26 to April 27, stopping after 2 pts due to low rate of PD-L negativity, maintaining >9% power to detect the target difference in ORR. PD-L testing labs changed in April 26. Prior to this time, QualTek PD-L positive was defined as % on tumor or TILs. Using the Dako 22C3 antibody, positive was defined as tumor PD-L combined positive score (CPS) %. 46 pts were screened to enroll 58 pts. Of screened pts, median stromal TILs was % (mean: 4.8%, SD: 9.%, range: to 6%; n = 27); 52% of pts were PD-Lpos, with higher positivity rates while using the Dako assay compared with Qualtek (65% vs. 43%, P =.9). Median TILs of pts in the PD-Lpos cohort was 2% (mean: 8.%, SD:.2%, range: to 4%) and % (mean:.2%, SD: 2.2%, range: to 5%) in the PD-Lneg cohort. Of enrolled pts, median age was 5 yrs (range: 28 72), 69% had visceral metastases. 29% of pts received prior pertuzumab, 72% had prior T-DM, 4% prior lapatinib. 38% of pts were ER-positive, 62% were ERnegative. Median TILs in enrolled ER pos and ER neg pts were.5% and 2.%, respectively. PD-L positivity rates were also not significantly different by ER status (p =.5). 3. Nancy U, Lin, Alisha Stein, Alan Nicholas, Anita M. Fung, Priya Kumthekar, Nuhad K. Ibrahim, Mark D. Pegram. Planned interim analysis of PATRICIA: An open-label, single-arm, phase II study of pertuzumab (P) with high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression post radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC). DOI:.2/JCO _suppl.274. Journal of Clinical Oncology 27;35(5 Suppl): BACKGROUND: There is currently no clear standard of care to address the management of recurring/multiple intracranial metastases post RT in HER2-positive MBC. The ongoing PATRICIA study (NCT ) is evaluating the safety and efficacy of P in combination with high-dose h for patients with HER2-positive MBC with CNS metastases who have CNS progression following RT. Reported herein are results from the protocol-specified interim analysis of PATRICIA. METHODS: All eligible patients must have measurable ( mm) CNS progression post RT, and stable non-cns disease. Patients receive P (84-mg loading dose, then 42 mg every 3 weeks) and high-dose h (6 mg/kg weekly). The primary efficacy endpoint is objective response rate (ORR) in the CNS per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria. The interim analysis was planned after 5 patients were enrolled and had 2 left ventricular ejection fraction (LVEF) measurements, 2 cycles of study drugs, and 2 response measurements. The study would proceed to full enrollment (n = 4) if objective response or stable disease in the CNS was observed in of 5 patients and <2 of 5 patients develop congestive heart failure (CHF) related to P or H. RESULTS: As of Sept 6, 26, 5 patients had been enrolled across 9 sites. Median treatment duration was 4.4 (range.2 8.3) months. Six patients discontinued treatment (5 for disease progression; for symptomatic deterioration). Range for duration of response was months. There were no new safety signals for P combined with high-dose h treatment. No patients had CHF or a clinically significant drop in LVEF. CONCLUSIONS: Based on early evidence of clinical benefit (ORR 2%) and a lack of new safety signals, the safety 2
3 and futility boundaries for PATRICIA have been passed and study enrollment continues. Clinical trial information: NCT Efficacy within CNS per RANO-BM criteria (%) Complete response (CR) Partial response (PR) 3 (2) Stable disease (SD) 9 (6) Disease progression 3 (2) ORR a 3 (2) 95% CI CR + PR + SD 4 months 6 (4) 95% CI a CR or PR 4. Tripathy D, Sohn J, Im S-A, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz S, Chow L, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu Y-S. First-line ribociclib vs. placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MOLEESA-7 trial. DOI:.58/ SABCS7-GS2-5. BACKGROUND: Endocrine therapy (ET) with ovarian function suppression is an established first-line treatment for pre- and peri-menopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2 ) advanced breast cancer (ABC). Addition of ribociclib (orally bioavailable, selective cyclin-dependent kinase [CDK] 4/6 inhibitor) to first-line ET prolonged progression-free survival (PFS) in a Phase III trial of postmenopausal women with HR+, HER2 ABC (MOLEESA-2). Here we report results from MOLEESA-7 (NCT22782), the first doubleblind, randomized, Phase III trial evaluating ribociclib + tamoxifen/non-steroidal aromatase inhibitor (NSAI) and goserelin specifically in pre- and peri-menopausal patients. METHODS: Pre- or peri-menopausal women with HR+, HER2 ABC who had received line of chemotherapy and no prior ET for ABC were randomized (:) to ribociclib (6 mg/day, 3-weeks-on/-week-off) or placebo in combination with either tamoxifen (2 mg/day) or an NSAI (letrozole [2.5 mg/day] or anastrozole [ mg/day]) + goserelin (3.6 mg every 28 days). The primary endpoint was locally assessed PFS. Secondary endpoints included overall response rate (ORR), clinical benefit rate (CBR), and safety. RESULTS: 672 patients were enrolled. Baseline patient characteristics were balanced between treatment arms. The primary analysis was conducted after 38 events had occurred; median time from randomization to data cut-off date was 9.2 months. The study met its primary objective: PFS was significantly improved in the ribociclib arm (median PFS = 23.8 months; 95% CI: 9.2 not reached) vs. the placebo arm (median PFS = 3. months; 95% CI:. 6.4), with a hazard ratio of.553 (95% CI: ; p = ). Subgroup analyses demonstrated consistent PFS benefits for ribociclib vs. placebo. In patients with measurable disease at baseline, ORR was 5% vs. 36% (ribociclib vs. placebo arm; P = ) and CBR was 8% vs. 67% (P = ). The most frequent all-grade adverse events (Aes; 25% of patients; ribociclib vs. placebo arm) were neutropenia (76% vs. 8%), hot flush (34% vs. 34%), nausea (32% vs. 2%), leukopenia (3% vs. 6%), and arthralgia (3% vs. 27%). Of these, neutropenia (6% vs. 4%) and leukopenia (4% vs. %) were the only Grade 3/4 events reported in 5% of patients (ribociclib vs. placebo arm). Febrile neutropenia (ribociclib vs. placebo arm) occurred in 2% vs. <% of patients. Grade 3/4 QT prolongation (ribociclib vs. placebo arm) was reported in % vs. <% of patients. Aes leading to permanent discontinuation of ribociclib + tamoxifen/ NSAI + goserelin vs. placebo + tamoxifen/nsai + goserelin occurred in 4% vs. 3% of patients. CONCLUSIONS: MOLEESA-7, the first dedicated trial investigating a CDK4/6 inhibitor in pre- and peri-menopausal women with HR+, HER2 ABC, demonstrated that addition of ribociclib to first-line ET (tamoxifen/nsai + goserelin) significantly prolonged PFS and had a manageable safety profile. The trial validates the clinical utility of ribociclib with multiple endocrine therapies, including tamoxifen, in premenopausal women with HR+, HER2 ABC. 5. Goetz MP, O Shaughnessy J, Sledge Jr GW, Martin M, Lin Y, Forrester T, Mockbee C, Smith IC, Di Leo A, Johnston S. The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MORCH 2 and 3 studies. DOI:.58/ SABCS7-GS6-2. BACKGROUND: Abemaciclib is an orally administered, selective inhibitor of cyclin-dependent kinases 4 & 6 that is dosed on a twice daily continuous schedule. Abemaciclib has demonstrated clinical efficacy with a generally tolerable safety profile in patients with hormone receptorpositive (HR+), human epidermal growth factor receptor 2-negative (HER2 ) advanced breast cancer in combination with fulvestrant in MORCH 2 (NCT2773) and in combination with non-steroidal aromatase inhibitors (NSAI) in MORCH 3 (NCT224662). These analyses were conducted to evaluate if patient and disease characteristics may better inform in whom and when abemaciclib should be initiated to define optimal treatment strategies. METHODS: MORCH 2 and 3 enrolled patients with HR+, HER2 advanced breast cancer. In MORCH 3
4 2, patients whose disease had progressed while receiving endocrine therapy were treated with abemaciclib/placebo plus fulvestrant. In MORCH 3, patients were treated with abemaciclib/placebo plus NSAI as initial therapy for advanced disease. An exploratory pooled analysis of the two studies was performed to determine significant prognostic factors. Efficacy results (progression-free survival [PFS] and objective response rate [ORR] in patients with measurable disease) were examined for patient subgroups corresponding to each of the identified significant prognostic factors. Subpopulation treatment effect pattern plot (STEPP) methodology was performed to examine the association between treatment-free interval (TFI) following adjuvant endocrine therapy and outcomes of endocrine therapy alone or in combination with abemaciclib in MON- ARCH 3. RESULTS: Analyses of clinical factors in over patients confirmed the following to have prognostic value: bone-only disease, liver metastases, tumor grade, progesterone receptor (PgR) status, and ECOG performance status. Prognosis was poor in patients with liver metastases, PgR-negative tumors, and high-grade tumors. While all subpopulations benefited from the addition of abemaciclib to endocrine therapy regardless of prognosis, substantial benefit of abemaciclib was observed in poor prognosis subgroups, characterized by large increases in PFS (hazard ratios =.4 to.5) and ORR (over 3%). In addition, STEPP analysis of TFI on a subset of the MORCH 3 population showed that patients with the shortest TFI appeared to have a poorer prognosis and received more benefit from the addition of abemaciclib compared to patients with longer TFI. CONCLUSIONS: This exploratory analysis has provided data that could help optimize treatment strategies by identifying that patients with poor prognostic factors may receive greater benefit from the addition of abemaciclib to endocrine therapy. 6. Rugo HS, Barry WT, Moreno-Aspitia A, Lyss A, Huebner L, Mayer EL, Naughton M, Layman RM, Carey LA, Somer RA, Toppmeyer D, Velasco M, Perez EA, Hudis CA, Winer E. Long-term follow-up of CALGB 452/NCCTG N63H (Alliance): A randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) +/ bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (MBC). DOI:.58/ SABCS7-GS3-6. BACKGROUND: CALGB 452/NCCTG N63H (Alliance) compared weekly NP or Ix to P; most patients received bevacizumab. Ix was inferior to P, and NP was not superior with a trend toward inferiority. Toxicity was increased in the experimental arms compared to P (Rugo et al, JCO 25). We report long-term follow-up (FU) of this trial with an unplanned subset analysis in hormone receptor positive (HR+) and triple negative (TNBC) breast cancer. METHODS: Patients were randomized :: to receive P (9 mg/m 2 ), Ix (6 mg/m 2 ) or NP (5 mg/m 2 ) on a 3 week (wk) on, wk off schedule, stratified by prior adjuvant taxane use and hormone receptor status. B was initially given to all patients, but became optional in 3/2 and was added to stratification. The primary endpoint was progressionfree survival (PFS); secondary endpoints included safety and overall survival (OS). With a target N = 9 patients, the study was powered to detect a hazard ratio of.36 (median PFS vs. 3.6 months). Eligibility included no prior chemotherapy for MBC, >2 mo from adjuvant P and measurable disease. RESULTS: 799 patients were randomized between /8 and/ (283 to P, 27 to NP, 245 to Ix); 98% received bevacizumab. 68% (546) had HR+ disease, 25% (2) had TNBC. Median FU is 5 years. Median PFS is unchanged at.8, 9.2 and 7.4 mo for P, NP and Ix with hazard ratios (95% CIs) of.3 (.94.34) and.44 (.2.72) for NP and Ix to P, respectively. Median OS was 27., 24.2 and 23.6 months for P, NP and Ix with hazard ratios of. (.9.34) and.3 (.7.57) for NP and Ix to P, respectively. The effects of NP vs. P on PFS and OS were significantly modified by subtype (interaction p =.8 and.73), whereas Ix vs. P was unchanged (interaction p s >.9, Table ). More patients discontinued treatment due to adverse events in the experimental arms (4 vs. 27 vs. 23% for P, NP and Ix). CONCLUSION: In patients with chemotherapy-naive MBC, Ix was inferior to P for PFS, and P was better tolerated than either NP or Ix. In this retrospective subset analysis, Ix and NP were inferior to P in HR+ disease, with a suggestion of improved PFS and OS with NP in patients with TNBC. Further investigation is required to explain and validate the subtype specificity seen in this exploratory analysis. TABLE TNBC, PFS HR+, PFS TNBC, OS HR+, OS P (mo) NP (mo) NP to P; HR (95% CI) (.55.2) (.4.59) (.5.7) (.99.58) 2 Ix (mo) Ix to P, HR (95% CI) (.99.96) (.2.86) (.9.82) (.7.7) 4 Interaction tests:. p =.8; 2. p =.73; 3. p =.96; 4. p =.92. mo, months; HR, hazard ratio. 4
5 7. Bardia A, Vahdat LT, Diamond J, Kalinsky K, O Shaughnessy J, Moroose RL, Isakoff SJ, Tolaney SM, Santin AD, Abramson V, Shah NC, Govindan SV, Maliakal P, Sharkey RM, Wegener WA, Goldenberg DM and IA Mayer. Sacituzumab govitecan (IMMU-32), an anti-trop-2-sn-38 antibody-drug conjugate, as 3rdline therapeutic option for patients with relapsed/ refractory metastatic triple-negative breast cancer (mtnbc): efficacy results. DOI:.58/ SABCS7-GS-7. BACKGROUND: mtnbc has an aggressive course with limited therapeutic options. Sacituzumab govitecan (IMMU-32) is a novel antibody drug conjugate consisting of SN-38, the active metabolite of the topoisomerase I inhibitor, irinotecan, conjugated to a humanized mab targeting Trop-2, which is highly expressed in most epithelial cancers, including TNBC. A phase I/II basket trial (NCT63552) was conducted in patients (pts) with multiple, advanced epithelial cancers. We previously reported preliminary results in mtnbc (N = 69; objective response rate [ORR] = 3%, Bardia et al., JCO 27;35:24 248). In 26, sacituzumab govitecan was granted Breakthrough Designation based on this encouraging data, and we resumed enrollment in a more defined patient population ( 3rd-line setting in mtnbc). METHODS: Pts received sacituzumab govitecan on days & 8 of a 2-day cycle until progression or unacceptable toxicity. Eligibility included >2 prior lines of therapy for metastatic disease, measurable disease by CT or MRI and prior taxane. Efficacy was assessed locally by RECIST. and confirmed by independent centralized blinded review. ORR, DOR, progression-free survival (PFS) and overall survival (OS) were determined. Adverse events (CTCAE v4.), immunogenicity, and Trop-2 expression in archived tumor samples, when available, were evaluated. RESULTS: mtnbc pts (9 female, male; median age 55 yrs, range 3 8), including 53 from the previously reported cohort of 69 pts who had received 2 prior regimens for metastatic disease, were accrued between 7/23 and 2/27. As of data cutoff on 6/3/27, 7 are deceased, 23 in long-term followup, and 6 still on treatment. All pts were treated at the mg/kg IMMU-32 dose level, receiving 4.5 median doses (range 88). Treatment was well tolerated, with no treatment-related deaths, 2 treatment discontinuations for toxicity, and no anti-drug antibodies detected. Grade 3 toxicity ( %) included neutropenia, 39%; leukopenia, 4%; anemia, %; the incidence of febrile neutropenia was low (7%). By local radiologist assessment, the ORR is 34% (37/), including 3 CRs and 34 PRs, the clinical benefit rate (CBR: CR+PR+SD>6 mo.) is 46%, the KM median DOR and PFS are 7.6 mo. (95% CI: 4.8 to.3) and 5.5 mo. (95% CI: 4.8 to 6.6), respectively, including % ( pts) with long-term PFS (2 to 3+ mo.), and the KM median OS is 2.7 mo. (95% CI:.8 to 3.6). Results of the independent central blinded review along with sensitivity analyses of prior treatment regimens, including checkpoint inhibitor use, and exploratory biomarker analysis of Trop-2 expression will be presented at the meeting. CONCLUSIONS: Sacituzumab govitecan demonstrated significant clinical activity as a single agent in the 3rd-line setting for patients with relapsed/refractory mtnbc. Given the high unmet medical need, data from this trial is being submitted for consideration of accelerated approval, and a global confirmatory randomized Phase III trial (NCT ) is underway. Additional studies including rational combinations are currently being evaluated for mtnbc and other breast cancer subsets. 8. Litton J, Rugo HS, Ettl J, Hurvitz S, Gonçalves A, Lee K-H, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im Y-H, Quek RGW, Tudor IC, Hannah AL, Eiermann W, Blum JL MD. EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician s choice of therapy in patients with advanced breast cancer and a germline BRCA mutation. DOI:.58/ SABCS7-GS6-7. BACKGROUND: Talazoparib (TALA) is a highly potent, dual-mechanism PARP inhibitor that inhibits the PARP enzyme and effectively traps PARP on single-stranded D breaks, preventing D damage repair and causing cell death in BRCA/2-mutated cells. METHODS: EMBRACA is an open-label, randomized, 2-arm, phase 3 trial comparing the efficacy and safety of TALA ( mg/day) with standard single-agent physician s choice of therapy (PCT) (capecitabine, eribulin, gemcitabine, or vinorelbine) in patients with advanced breast cancer (abc) and a germline BRCA/2 mutation (gbrcamut). The primary objective was PFS assessed by blinded independent central review (BICR). Secondary objectives: OS, ORR, CBR at 24 weeks (CBR24), and safety. Exploratory objectives: patient-reported QoL and DOR. Eligibility criteria: age 8 years; HER2-negative abc; deleterious or suspected deleterious gbrcamut; 3 prior cytotoxic regimens for abc; and ECOG PS 2. Prior platinum was allowed. Patients were randomized 2: and stratified by receptor status, extent of prior therapy, and CNS metastases (NCT945775). RESULTS: 43 patients were randomized (median age 46 years; 54% hormonereceptor [HR]+ BC; 45% BRCA+ and 55% BRCA2+; 55% ECOG PS = ; 38% chemo-naïve for abc; 8% prior platinum; 5% CNS metastases); 287 were assigned to TALA and 44 to PCT ( TALA, 8 PCT patients were not treated). Median duration of exposure was 6. and 3.9 months, respectively; TALA had a relative dose intensity of 87%. At 62% PFS data maturity: Improved clinical benefit was seen in all subsets including those with HR+ BC (HR.47; 95% CI.32.7) and CNS metastasis (HR.32; 95% CI.5.88). There was a significant delay in the time to deterioration in global health status (GHS)/QoL for TALA vs. PCT (HR.38; 95% CI.26.55; P <.]. Grade 3 4 hematologic adverse events (AEs) occurred in 55% TALA (mainly anemia)/39% PCT (mainly 5
6 TALA PCT Hazard Ratio/ Odds Ratio PFS by BICR, mo (95% CI) OS [interim], mo (95% CI) ORR by INV, % (95% CI) DOR by INV, mo (IQR) CBR24 by INV, % (95% CI) 8.6 ( ); n = ( ); n = % ( ); n = (2.8.2); n = % ( ); n = ( ); n = ( ); n = % ( ); n = 4 3. ( ); n = 3 36.% ( ); n = 44 (P value).542 (<.).76 (.5) 4.99 (<.).43 (.5)* 4.28 (.) neutropenia). Grade 3 4 non-hematologic AEs were seen in 32% TALA/38% PCT; TALA was associated with fewer gastrointestinal disorders (5.6% vs..9%) and skin/ subcutaneous tissue disorders (.7% vs. 5.6%) than PCT. Grade 3 4 serious AEs were observed in 26% TALA/25% PCT. AEs associated with permanent study drug discontinuation occurred in 8% TALA/% PCT. AE resulting in death occurred in 2.% TALA/3.2% PCT. CONCLUSIONS: Single-agent TALA significantly prolonged PFS by BICR in HER2-negative abc patients with a gbrcamut compared to PCT; all key secondary efficacy endpoints demonstrated benefit with TALA, with a significant delay in time to deterioration in GHS/QoL. TALA was generally well tolerated with minimal non-hematologic toxicity and few AEs associated with treatment discontinuations. INV, investigator. *Not a randomized subset. 6
San Antonio Breast Cancer Symposium December 5-9, 2017
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, as 3rd-line Therapeutic Option for Patients With Relapsed/Refractory Metastatic Triple-Negative Breast Cancer (mtnbc): Efficacy
More informationHighlights of. Metastatic & Advanced Breast Cancer
Highlights of Metastatic & Advanced Breast Cancer 1 Financial Disclosure(s) I currently have or have had the following relevant financial relations to disclose: Speaker s Bureau: Novartis 2 Off Label Use
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationKarcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski
Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,
More informationRIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationFirst-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study
First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More informationAdvanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationDisease Update: Metastatic Breast Cancer
Disease Update: Metastatic Breast Cancer Aimee Faso, PharmD, BCOP, CPP Oncology Clinical Specialist, GI/Breast UNC Hospitals and Clinics August 2015 Objectives Identify treatment choices of metastatic
More informationDennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationTarge:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationNew chemotherapy drugs in metastatic breast cancer. Guy Jerusalem, MD, PhD
New chemotherapy drugs in metastatic breast cancer Guy Jerusalem, MD, PhD MBC Patients survival over time Median survival increases over time, but is still measured in months This is not yet a chronic
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationHer 2 Positive Advanced Breast Cancer: From Evidence to Practice
Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine,
More information2014 San Antonio Breast Cancer Symposium Review
2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01
More informationProgress in the management of metastatic breast cancer in 2018: Is a cure in the horizon?
Progress in the management of metastatic breast cancer in 2018: Is a cure in the horizon? By Gerardo Colón-Otero, MD Mayo Clinic Florida Address correspondence to: Gerardo Colón-Otero, MD Professor of
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationEndocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationJosé Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationUpdate in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
More informationScience-Based Innovation-Focused ADC Company. Corporate Overview June 2018
Science-Based Innovation-Focused ADC Company Corporate Overview June 2018 Forward-Looking Statements This presentation, in addition to historical information, contains certain forwardlooking statements
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationASCO and San Antonio Updates
ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs
More informationThe benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies
The benefit of in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies Matthew P. Goetz¹, Joyce O Shaughnessy², George W. Sledge Jr.³, Miguel Martin⁴, Yong Lin⁵,
More informationPROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
More informationPoint of View on Triple Negative: Metastatic setting Dott.ssa llaria Portarena MD, PhD UOSD Oncologia Medica Policlinico Tor Vergata
Point of View on Triple Negative: Metastatic setting Dott.ssa llaria Portarena MD, PhD UOSD Oncologia Medica Policlinico Tor Vergata Roma, 29 Gennaio 2018 San Antonio Breast Cancer Symposium December 5-9,
More informationNew Drug Development in HER2+ Breast Cancer
New Drug Development in HER2+ Breast Cancer Philippe Aftimos, M.D. Senior Research Physician Clinical Pharmacology Unit Institut Jules Bordet Background Amplification of HER2 occurs in approximately 20%
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast
More informationMetastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationOpen Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
More informationPost-ASCO 2017 Cancer du sein Triple Négatif
Post-ASCO 217 Cancer du sein Triple Négatif A.Ladjeroud, K.Bouzid Centre Pierre et Marie Curie- Alger Oran, 3 Septembre 217 Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination
More informationMONALESSA-7: Phase III placebo-controlled study of ribociclib and tamoxifen/nsai + goserelin
First-line ribociclib or placebo combined with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer:
More informationASCO 2018 Breast Cancer updates. June 29 th 2018 Einav Gal-Yam Sheba MC
ASCO 2018 Breast Cancer updates June 29 th 2018 Einav Gal-Yam Sheba MC Early BC Adjuvant Chemotherapy benefit in HR-pos Nneg BC TAILORX Slide 1 Presented By Joseph Sparano at 2018 ASCO Annual Meeting TAILORx
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationCancers du Sein Métastatiques
Cancers du Sein Métastatiques Véronique Diéras Journée Laurence Leroyer Rennes 18 mai 2018 Plan ESME Inhibiteurs CDK 4/6 RH+ Inhibiteurs PARP Anticorps drogue-conjugués Perspectives 2018-2019 ESME Time
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationExpert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides
Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer Reference Slides Overview BRCA Mutations and Breast Cancer Patients with BRCA mutations have an estimated 55% to 65% cumulative
More informationBreast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
More informationInibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici Laura Orlando UOC Oncologia & Breast Unit Brindisi Verona 22/04/2016 Summary Studi con
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More informationLa malattia triplo negativa metastatica: quali trattamenti nella pratica clinica?
2018 CARCINOMA MAMMARIO: I TRAGUARDI RAGGIUNTI E LE NUOVE SFIDE La malattia triplo negativa metastatica: quali trattamenti nella pratica clinica? Roma, 27 Ottobre 2018 Relatore: Francesca Poggio Disclosure
More informationRuth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory University, Chief of
Review of triple negative breast cancer and new agents GASCO Review of SABCS 2014 January 10 th 2015, Atlanta, GA Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology
More informationTargeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical
More informationMEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014
MEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014 Dr Thomas Yau Clinical Assistant Professor MBBS(HK), MRCP (UK), FHKCP (Med Onc), FHKAM( Medicine), FRCP(London) Queen Mary Hospital The University of Hong Kong
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018 HER2-positive Breast Cancer Adjuvant
More informationPolicy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015
Medication Policy Manual Topic: Perjeta, pertuzumab Committee Approval Date: May 9, 2014 Policy No: dru281 Date of Origin: September 24, 2012 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More informationTriple negative breast cancer -neoadjuvant and adjuvant systemic therapy
Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy Sung-Bae Kim, MD, PhD Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea DISCLOSURE
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationBreast : ASCO Abstracts for Review
Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationBreast Cancer Immunotherapy. Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy
Breast Cancer Immunotherapy Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy Conflict of Interest I have the following financial relationships to disclose:
More informationBREAST CANCER SLIDE DECK 2017 Selected abstracts from:
BREAST CANCER SLIDE DECK 2017 Selected abstracts from: 2017 ASCO ANNUAL MEETING 2 6 June 2017 Chicago, USA Supported by Eli Lilly and Company. Eli Lilly and Company has not influenced the content of this
More informationSystemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
More informationLo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento
Lo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento TRASTUZUMAB most important breakthrough in the management of BC Trastuzumab
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationCohort D Xentuzumab + abemaciclib + fulvestrant (500 mg/month) Key exclusion criteria RP2D-4 NSCLC. Cohort F Xentuzumab + abemaciclib + fulvestrant
A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors, including hormone receptor-positive, HER2-negative breast cancer (plus endocrine therapy) Douglas
More informationPredicting outcome in metastatic breast cancer
Predicting outcome in metastatic breast cancer Aleix Prat, MD, PhD Medical Oncology Department Translational Genomics and Targeted Therapeutics in Solid Tumors Monday, 15 th January, Manchester, UK Disclosures
More informationESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT
ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT DOCETAXEL, OXALIPLATIN AND FLUOROURACIL/LEUCOVORIN (FLOT) FOR RESECTABLE
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationESMO Preceptorship Breast Cancer. Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Istituto Europeo di Oncologia
ESMO Preceptorship Breast Cancer Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Istituto Europeo di Oncologia Outline Rational for immune-based therapy in BC How to
More informationScience-Based Innovation-Focused ADC Company. Corporate Overview August 2018
Science-Based Innovation-Focused ADC Company Corporate Overview August 2018 Forward-Looking Statements This presentation, in addition to historical information, contains certain forwardlooking statements
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationHighlitghs in MBC First and second line endocrine treatments. Antonio Frassoldati Oncologia Clinica Ferrara
Highlitghs in MBC First and second line endocrine treatments Antonio Frassoldati Oncologia Clinica Ferrara Which clinical scenario have to face First line therapy with today? Untreated metastatic breast
More informationCancer du sein métastatique et amélioration de la survie Pr. X. Pivot
Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationPositive HER-2 tumor. How to incorporate the new drugs into neoadjuvance
Oncology Department Vall d Hebron University Hospital Barcelona. Spain Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance Javier Cortés June/2013 MD Anderson experience Buzdar et
More informationTNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 The problem with TNBC 1. Generally more aggressive 2. ONLY chemotherapy 3. No other
More informationMultimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
More informationNuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Prima linea di trattamento
Nuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Prima linea di trattamento Prof. Sabino De Placido Dip. di Endocrinologia ed Oncologia
More informationEnfermedad con sobreexpresión de HER-2 neu
Enfermedad con sobreexpresión de HER-2 neu Elsa Dalmau Parc Taulí Sabadell. Hospital Universitari. Enfermedad con sobreexpresión de HER-2 neu ÍNDICE Neoadyuvancia Adyuvancia Enfermedad avanzada Enfermedad
More informationPage. Objectives: Hormone Therapy Resistance: Challenges and Opportunities. Research Support From Merck
Hormone Therapy Resistance: Challenges and Opportunities Pamela. N. Munster, MD University of California, San Francisco Financial Disclosures Research Support From Merck Objectives: Understanding the current
More informationSponsor / Company: Sanofi Drug substance(s): SAR (iniparib)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationONT-380 and HER2+ Breast Cancer
ONT-380 and HER2+ Breast Cancer Diana F. Hausman, MD CMO, VP Clinical Development Oncothyreon Inc. PNW Bio February 10 2015 Copyright 2014 Copyright Oncothyreon 2014 Oncothyreon Oncothyreon Leading Oncology
More information